Oxidative Medicine and Cellular Longevity

Harnessing Oxidative Stress as an Innovative Target for Cancer Therapy


Status
Published

Lead Editor

1University of Manitoba, Winnipeg, Canada

2University of Alberta, Edmonton, Canada

3University of Texas MD Anderson Cancer Center, Houston, USA

4Universitat Lausanne Schweiz, Lausanne, Switzerland


Harnessing Oxidative Stress as an Innovative Target for Cancer Therapy

Description

In the last few decades, the understanding of oxidative stress in cancer has come into focus. Specifically, the various functions of reactive oxygen species (ROS) play a role in the progression of cancer and how this can be targeted for therapy.

In the recent literature, many significant contributions to understanding how oxidative stress is regulated in cancer and how this can be targeted for therapy have been achieved. This special issue aims at creating a multidisciplinary platform for recent advances in oxidative stress and how this is used for cancer therapies. This issue accepts high quality articles containing original research results and review articles of significant merit and editorial commentary of research articles. Readers of this journal will know more about this exciting area of cancer research and how it can be applied to cancer therapy through the lens of oxidative medicine.

Potential topics include but are not limited to the following:

  • Autophagy
  • Hypoxia
  • Metabolism
  • Cell death
  • Cell survival
  • Signal transduction
  • Antioxidants
  • Microenvironment
  • Chemotherapeutic mechanism of action
  • Translational medicine
Oxidative Medicine and Cellular Longevity
 Journal metrics
See full report
Acceptance rate8%
Submission to final decision133 days
Acceptance to publication34 days
CiteScore10.100
Journal Citation Indicator-
Impact Factor-
 Submit Evaluate your manuscript with the free Manuscript Language Checker

We have begun to integrate the 200+ Hindawi journals into Wiley’s journal portfolio. You can find out more about how this benefits our journal communities on our FAQ.